Evidence map›Paper›PMID 30896460›Full record

ArticleJournal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases2019

Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.

Mark E McClure, James Wason, Seerapani Gopaluni, Joanna Tieu, Rona M Smith, David R Jayne, Rachel B Jones

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Top ten tips in managing ANCA vasculitis.Clinical kidney journal · 2025
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mark E McClureFrom the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge University Hospitals.
James WasonMRC Biostatistics Unit, University of Cambridge, Cambridge.
Seerapani GopaluniFrom the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge University Hospitals.
Joanna TieuFrom the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge University Hospitals.
Rona M SmithFrom the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge University Hospitals.
David R JayneFrom the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge University Hospitals.
Rachel B JonesFrom the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge University Hospitals.
Addenbrooke's Hospital · GBUniversity of Cambridge · GBMRC Biostatistics Unit · GB

Funding

Medical Research Council MC_UU_00002/6
6 · The paper itself

Abstract

introductionThe value of antineutrophil cytoplasmic antibody (ANCA) measurements among patients with an established diagnosis of ANCA-associated vasculitis (AAV) to assess disease activity or predict relapse remains controversial, but recent evidence suggests a possible role for rituximab-treated patients. PATIENTS AND

methodsAll patients with active vasculitis and positive proteinase 3 (PR3)-ANCA who were starting a 2-year treatment course of rituximab for induction of remission at Addenbrooke's Hospital between January 2011 and January 2016 were included in this study. Common department practice consists of 6 g of rituximab given over 2 years, concomitant corticosteroids (0.5-1.0 mg/kg) with rapid taper over 3 months, and cessation of oral maintenance immunosuppressive agents at time of first rituximab dose. Clinical and laboratory data were collected retrospectively using electronic patient records.

resultsFifty-seven patients with current PR3-ANCA positivity were included in the analysis. Median follow-up was 59 months. PR3-ANCA negativity was achieved in 25 patients (44%) with a median time of 14 months. Clinical remission was achieved in 53 patients (93%) with a median time of 3 months. Among the 53 patients who achieved remission during follow-up, 24 (45%) relapsed with a median time to relapse of 36 months from remission. Both PR3-ANCA-negative status and 50% reduction in PR3-ANCA from baseline (as time-varying covariates) were significantly associated with a longer time to relapse (PR3-ANCA-negative status: hazards ratio, 0.08 [95% confidence interval, 0.01-0.63, p = 0.016]; 50% reduction in PR3-ANCA: hazards ratio, 0.25 [95% confidence interval, 0.18-0.99, p = 0.046]).

conclusionsAchieving and maintaining PR3-ANCA negativity after rituximab was associated with longer-lasting remission.

Indexed as

Antibodies, Antineutrophil CytoplasmicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisBiomarkersEnzyme-Linked Immunosorbent AssayFemaleGlucocorticoidsHumansImmunologic FactorsMaleMiddle AgedMyeloblastinRemission InductionRituximabAntibodies, Antineutrophil CytoplasmicBiomarkersGlucocorticoidsImmunologic FactorsMyeloblastinRituximab

Identifiers

PMID30896460
PMCPMC7612177
OpenAlexW2933762917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.